pharmaceutical impurity analysis solutions - Lcms-connect.com

AmAU40Chlorhexidine, spiked with 1 ppm PGIsDAD 260 nm30201002 3 4 5 6 7min1PGI 5, 166.1>130.0 (80.4%)010×10 -21PGI 4, 163.1>120.0 (98.3%)PGI 6, 150.1>108.0 (3.8%, coelution with API)B2000PGI 5, 166.1>130.00×10 -110×10 -110PGI 7, 129.1>93.0 (79.1%)PGI 3, 136.1>121.0 (101.7%)100010002000PGI 4, 163.1>120.0PGI 6, 150.1>108.0PGI 3, 136.1>121.0×10 21PGI 8, 128.1>93.0 (Present in API, > 20 ppm)500PGI 7, 129.1>93.00×10 -21PGI 2, 126.1>111.0 (96.0%)1000PGI 8, 128.1>93.00×10 -110PGI 9, 122.1>105.1 (98.5%)100500PGI 2, 126.1>111.0PGI 9, 122.1>105.1×10 -210PGI 1, 119.1>92.0 (89.6%)2 3 4 5 6 7Counts (%) vs. Acquisition Time (min)250PGI 1, 119.1>92.00.8 1 1.2 1.4 1.6 1.8 2 2.2 2.4Counts vs. Acquisition Time (min)Figure 15. DAD result and quantifier MRM transitions for the analysis of a chlorohexidine sample spiked with PGIs. A comparison is shown between results achievedwith 150 mm column (A) and 50 mm column (B) Agilent ZORBAX Eclipse Plus C18 RRHD (2.1 mm id, 1.8 μm) columns. Transitions and calculated recoveries are alsoindicated. See Agilent publication 5990-5732EN.22